Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Navid Malik Insider Profile
4 Followers
Navid Malik, Director at Northwest Biotherapeutics, holds 0.00 shares in Northwest Biotherapeutics (Ticker: NWBO). Most recently, Navid Malik Bought $570,000 shares of Northwest Biotherapeutics on Dec 01, 2023 for an estimated value of 465.70K.
Navid Malik has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Navid Malik does not currently own shares as a corporate insider.
A breakdown of Navid Malik's holdings
Insider Roles
Director
Roles that Navid Malik holds in companies
Most Profitable Insider Trade
The most profitable trade made by Navid Malik
Navid Malik's Trading History
List of latest transactions for each holding click on a transaction to see Navid Malik's performance on stock
You May Also Like
Navid Malik insider profile FAQ
What is the percentage of profitable transactions made by Navid Malik?
The percentage of profitable transactions made by Navid Malik is ―.
What is the average return per transaction made by Navid Malik?
The average return per transaction made by Navid Malik is ―.
What stocks does Navid Malik hold?
Navid Malik holds: NWBO stocks.
What was Navid Malik’s latest transaction?
Navid Malik latest transaction was an Informative Buy of $465.70K.
What was Navid Malik's most profitable transaction?
Navid Malik’s most profitable transaction was an Informative Buy of NWBO stock on December 1, 2023. The return on the trade was -43.20%.
What is Navid Malik's role in Northwest Biotherapeutics?
Navid Malik's role in Northwest Biotherapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.